A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) Malignancies

PHASE2CompletedINTERVENTIONAL
Enrollment

166

Participants

Timeline

Start Date

June 12, 2017

Primary Completion Date

March 10, 2020

Study Completion Date

January 17, 2022

Conditions
Various Advanced Cancer
Interventions
BIOLOGICAL

Nivolumab

Specified dose on specified days

BIOLOGICAL

Ipilimumab

Specified dose on specified days

Trial Locations (54)

852

Local Institution - 0018, Hong Kong

2031

Local Institution - 0022, Randwick

3052

Local Institution - 0034, Parkville

3168

Local Institution, Clayton

4101

Local Institution - 0035, Sth Brisbane

6009

Local Institution - 0033, Nedlands

10021

Local Institution - 0004, New York

10032

Local Institution - 0017, New York

19104

Local Institution - 0066, Philadelphia

20246

Local Institution - 0061, Hamburg

21287

Local Institution - 0005, Baltimore

28009

Local Institution - 0038, Madrid

29425

Local Institution, Charleston

32611

Local Institution - 0046, Gainesville

33076

Local Institution - 0029, Bordeaux

38105

Local Institution - 0012, Memphis

45147

Local Institution - 0060, Essen

45229

Cincinnati Children'S Hospital Medical Center, Cincinnati

46026

Local Institution - 0036, Valencia

49100

Local Institution - 0028, Angers

54500

Local Institution - 0064, Vandœuvre-lès-Nancy

59000

Local Institution - 0027, Lille

63110

Local Institution - 0044, St Louis

69008

Local Institution - 0025, Lyon

69120

Local Institution - 0063, Heidelberg

77030

Local Institution - 0042, Houston

80045

Local Institution - 0016, Aurora

90027

Local Institution - 0057, Los Angeles

97080

Local Institution - 0062, Würzburg

117997

Local Institution - 0048, Moscow

3109601

Local Institution - 0059, Haifa

5266202

Local Institution - 0058, Ramat Gan

60611-2605

Local Institution - 0011, Chicago

02215

Local Institution - 0043, Boston

90035-074

Local Institution - 0052, Porto Alegre

14784-400

Local Institution - 0051, Barretos

14048-900

Local Institution - 0053, Ribeirão Preto

04023-062

Local Institution - 0049, São Paulo

08270-070

Local Institution - 0050, São Paulo

M5G 1X8

Local Institution - 0021, Toronto

H4A 3J1

Local Institution - 0001, Montreal

G1V 4G2

Local Institution - 0002, Québec

13385 cedex 05

Local Institution - 0024, Marseille

75231 cedex 5

Local Institution - 0023, Paris

94805 CEDEX

Local Institution - 0026, VIillejuif

3015 GJ

Local Institution - 0007, Rotterdam

3584 EA

Local Institution - 0008, Utrecht

0027

Local Institution - 0067, Oslo

04-730

Local Institution - 0047, Warsaw

08950

Local Institution - 0037, Esplugues de Llobregat

171 76

Local Institution - 0065, Solna

WC1N 3JH

Local Institution - 0010, London

L12 2AP

Local Institution - 0013, Liverpool

NEI 4LP

Local Institution - 0015, Newcastle upon Tyne

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT03130959 - A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) Malignancies | Biotech Hunter | Biotech Hunter